Women had a lower probability of receiving any disease-modifying treatment (DMT) and were even less likely to get ...

Among 282 patients with pediatric-onset MS, 39% started high-efficacy therapy early (at ages 12-17), and 61% started late ...

Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, ...

A study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple ...

Key biomarkers identified can now predict disability progression in multiple sclerosis, offering potential for more ...

New research presented today at European Committee for Treatment and Research in Multiple Sclerosis 2024 reveals that ...

A new study reveals how gender disparities cause therapeutic inertia in MS treatment for women, highlighting delays and ...

Researchers have identified biomarkers that can predict disease progression in multiple sclerosis, which could lead to the ...

A short course of Mavenclad can provide long-term reductions in disease activity and disability progression in highly active ...

Rutgers Health researchers will enroll primary or secondary progressive multiple sclerosis (p-MS) patients to see if an ...

Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...

A study has revealed significant therapeutic inertia in the treatment of women with multiple sclerosis (MS), highlighting gender disparities that could impact long-term health outcomes for women of ...